Literature DB >> 6286786

Resistance of herpes simplex virus to adenine arabinoside and E-5-(2-bromovinyl)-2'-deoxyuridine: a physical analysis.

C S Crumpacker, L E Schnipper, P N Kowalsky, D M Sherman.   

Abstract

The physical map limits of DNA sequences within the DNA polymerase locus of herpes simplex virus (HSV) type 1 that define resistance mutations to adenine arabinoside (ara-A) and E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) were determined. Intertypic recombinants between HSV types 1 and 2, generated by marker rescue of temperature-sensitive mutations, had genome structures determined by restriction endonuclease analysis and were used to show that the resistance mutation for ara-Ar-1 is closely linked to the resistance mutations for phosphonoacetic acid (paar-1) and acycloguanosine (acvr-1) within a region of 2.6 kilobase pairs (kbp) in the HSV DNA polymerase locus. The resistance mutation for bvdur-1 is defined by a 2.9-kbp region that overlaps with the region defining resistance to the other three drugs but that is transferred separately. The DNA polymerase locus also contains a 2.2-kbp region that maps adjacent to and to the left of the region defining the bvdur-1 mutation which can be transferred separately and defines a region determining the HSV-1-specific sensitivity to BVDU in a manner analogous to that to acyclovir.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286786     DOI: 10.1093/infdis/146.2.167

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus.

Authors:  D M Coen; H E Fleming; L K Leslie; M J Retondo
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

2.  Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene.

Authors:  H J Field; D M Coen
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

3.  Mutation within the herpes simplex virus DNA polymerase gene conferring resistance to (R)-9-(3,4-dihydroxybutyl)guanine.

Authors:  H C Chiou; K M Kerns; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

4.  Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45.

Authors:  L E Holland; R M Sandri-Goldin; A L Goldin; J C Glorioso; M Levine
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Resistance of herpes simplex virus to antiviral agents. Is it clinically important?

Authors:  C Crumpacker
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

6.  Fine mapping and molecular cloning of mutations in the herpes simplex virus DNA polymerase locus.

Authors:  D M Coen; D P Aschman; P T Gelep; M J Retondo; S K Weller; P A Schaffer
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

7.  Physical mapping of two herpes simplex virus type 1 host shutoff loci: rescue of each ts mutation occurs with two unique cloned regions of the viral genome.

Authors:  J I Daksis; V L Chan
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

8.  Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus.

Authors:  C S Crumpacker; P N Kowalsky; S A Oliver; L E Schnipper; A K Field
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Herpes simplex virus mutants resistant to arabinosyladenine in the presence of deoxycoformycin.

Authors:  H E Fleming; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.

Authors:  A Poryo; R Wigand
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.